PETX - Aratana Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
4.48
-0.04 (-0.88%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close4.52
Open4.52
Bid4.32 x 2000
Ask4.99 x 500
Day's Range4.46 - 4.56
52 Week Range3.67 - 7.49
Volume98,041
Avg. Volume303,895
Market Cap211.28M
Beta2.40
PE Ratio (TTM)N/A
EPS (TTM)-1.17
Earnings DateAug 2, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.97
Trade prices are not sourced from all markets
  • PR Newswire11 days ago

    Aratana Therapeutics to Report Second Quarter 2018 Financial Results

    LEAWOOD, Kan. , July 10, 2018 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative therapeutics ...

  • When Will Aratana Therapeutics Inc (NASDAQ:PETX) Breakeven?
    Simply Wall St.25 days ago

    When Will Aratana Therapeutics Inc (NASDAQ:PETX) Breakeven?

    Aratana Therapeutics Inc’s (NASDAQ:PETX): Aratana Therapeutics, Inc., a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium.Read More...

  • ACCESSWIRElast month

    Breakfast Technical Briefing on Alkermes and Three Other Additional Biotech Stocks

    Research coverage has been initiated by WallStEquities.com on Aimmune Therapeutics Inc. (NASDAQ: AIMT), Alkermes PLC (NASDAQ: ALKS), Aratana Therapeutics Inc. (NASDAQ: PETX), and ARCA biopharma Inc. (NASDAQ: ABIO). The majority of Biotech companies research and develop products for the healthcare market.

  • PR Newswire2 months ago

    Aratana Therapeutics Files for FDA Approval of NOCITA® (bupivacaine liposome injectable suspension) Label Expansion

    LEAWOOD, Kan., June 1, 2018 /PRNewswire/ -- Aratana Therapeutics, Inc. (PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative therapeutics for dogs and cats, today announced the Company submitted a supplemental New Animal Drug Application (NADA) for NOCITA® (bupivacaine liposome injectable suspension) with the U.S. Food and Drug Administration's Center for Veterinary Medicine (CVM). The filing is intended to expand the NOCITA label to include its use in cats as a peripheral nerve block to provide regional post-operative analgesia following onychectomy. "We believe veterinarians are in need of safe and effective, non-opioid alternatives to provide pain relief to their feline and canine patients" explained Ernst Heinen, DVM, PhD, Chief Development Officer of Aratana Therapeutics.

  • PR Newswire2 months ago

    Aratana Therapeutics to Participate at Jefferies 2018 Global Healthcare Conference

    LEAWOOD, Kan. , May 22, 2018 /PRNewswire/ -- Aratana Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative therapeutics ...

  • PR Newswire2 months ago

    Aratana Therapeutics Appoints Craig Barbarosh and Lowell Robinson to its Board of Directors in Cooperation Agreement with Engaged Capital

    LEAWOOD, Kan., May 21, 2018 /PRNewswire/ -- Aratana Therapeutics, Inc. (PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative therapeutics for dogs and cats, today announced the Company has appointed Craig Barbarosh and Lowell Robinson to its Board of Directors (Board) in connection with a cooperation agreement with Engaged Capital, LLC ("Engaged Capital"). Mr. Barbarosh will be a member of the Board's Compensation Committee and Mr. Robinson will be a member of the Audit Committee.

  • ACCESSWIRE2 months ago

    Breakfast Technical Briefing on BioLine Rx and Three More Biotech Stocks

    LONDON, UK / ACCESSWIRE / May 17, 2018/ If you want a free Stock Review on BLRX sign up now at www.wallstequities.com/registration. In today's pre-market research, WallStEquities.com evaluates Aratana Therapeutics Inc. (NASDAQ: PETX), BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), BioDelivery Sciences International Inc. (NASDAQ: BDSI), and BioLine Rx Ltd (NASDAQ: BLRX).

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of PETX earnings conference call or presentation 4-May-18 12:30pm GMT

    Q1 2018 Aratana Therapeutics Inc Earnings Call

  • Barrons.com3 months ago

    [$$] Engaged Capital Seeks Seats on Aratana Therapeutics Board

    Source: InsiderScore.com Mudrick Capital Management revealed on April 30 that it is reviewing available options, including legal action, to halt the April 25 proposal by Thermo Acquisitions to merge with Globalstar. Mudrick stated in its filing that it believes such a combination is “ill-advised” and would “substantially dilute the holdings of minority shareholders of Globalstar for the benefit of the CEO.” It will reach out to other shareholders to discuss potential litigation against the proposed merger. Previously, on April 11, Mudrick had urged the board to seek alternatives to the financing offered by Thermo—and its chairman and CEO, James Monroe III—including its own offer to lend $150 million in nonconvertible credit.

  • ACCESSWIRE3 months ago

    Aratana Therapeutics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 4, 2018 / Aratana Therapeutics, Inc. (NASDAQ: PETX ) will be discussing their earnings results in their Q1 Earnings Call to be held on May 4, 2018 at 8:30 AM Eastern Time. ...

  • Associated Press3 months ago

    Aratana: 1Q Earnings Snapshot

    On a per-share basis, the Leawood, Kansas-based company said it had a loss of 19 cents. The results fell short of Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...

  • PR Newswire3 months ago

    Aratana Therapeutics Reports First Quarter 2018 Financial Results

    LEAWOOD, Kan. , May 3, 2018 /PRNewswire/ -- Aratana Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative therapeutics ...

  • GlobeNewswire3 months ago

    Recent Analysis Shows Waterstone Financial, Blue Bird, Proto Labs, American Assets Trust, MoSys, and Aratana Therapeutics Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, May 02, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Waterstone ...

  • 5 Drug Stocks Poised to Surpass on Earnings This Quarter
    InvestorPlace3 months ago

    5 Drug Stocks Poised to Surpass on Earnings This Quarter

    This prospective upside marks the maximum quarterly earnings growth pace in seven years. The report further predicts that 11 of the 16 Zacks sectors are projected to exhibit double-digit earnings growth in the to-be-reported quarter.

  • PR Newswire3 months ago

    Aratana Therapeutics to Report First Quarter 2018 Financial Results

    LEAWOOD, Kan. , April 12, 2018 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative therapeutics ...

  • PR Newswire4 months ago

    Aratana Therapeutics Confirms Receipt of Board Nominations

    LEAWOOD, Kan., April 5, 2018 /PRNewswire/ -- Aratana Therapeutics, Inc. (PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative therapeutics for dogs and cats, confirmed that it has received a notice of nomination of three director candidates for election to the Company's Board of Directors at the 2018 Annual Meeting of Stockholders from Engaged Capital, LLC and certain of its affiliated entities, which earlier today filed a Schedule 13D disclosing ownership of 5.2% of Aratana's outstanding shares. Aratana stockholders are not required to take any action at this time. Members of Aratana's Board and management have recently held discussions with representatives of Engaged Capital and those discussions are ongoing.

  • Aratana Therapeutics (PETX) Soars: Stock Adds 12.4% in Session
    Zacks4 months ago

    Aratana Therapeutics (PETX) Soars: Stock Adds 12.4% in Session

    Aratana Therapeutics (PETX) was a big mover last session, as the company saw its shares rise more than 12% on the day amid huge volumes.

  • Benzinga4 months ago

    Pet Therapeutic Entyce Can Drive Aratana Higher, Stifel Says In Upgrade

    Aratana Therapeutics Inc (NASDAQ: PETX ), which has a portfolio treatments for pet diseases and disorders, is likely to ride high on product momentum, according to Stifel.  The Analyst Analyst Jonathan ...

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of PETX earnings conference call or presentation 14-Mar-18 12:30pm GMT

    Q4 2017 Aratana Therapeutics Inc Earnings Call

  • American City Business Journals4 months ago

    Aratana raises $11.7M despite aborted stock offering

    The funds were raised through the sale of 2.39 million shares via an at-the-market sales agreement with Cowen and Co. LLC. The agreement, which Aratana (PETX) entered in December, would allow the company incrementally to sell up to $50 million worth of shares. Considering the most recent sales, Aratana may sell the remaining $38 million in stock.

  • Aratana raises $11.7M despite aborted stock offering
    American City Business Journals4 months ago

    Aratana raises $11.7M despite aborted stock offering

    Aratana Therapeutics Inc., a Leawood-based animal health company (Nasdaq: PETX), raised $11.7 million through a stock sales agreement.

  • Associated Press4 months ago

    Aratana reports 4Q loss

    On a per-share basis, the Leawood, Kansas-based company said it had a loss of 37 cents. Losses, adjusted for asset impairment costs, came to 19 cents per share. The results surpassed Wall Street expectations. ...

  • PR Newswire4 months ago

    Aratana Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results

    LEAWOOD, Kan. , March 13, 2018 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative therapeutics ...

  • When Can We Expect A Profit From Aratana Therapeutics Inc (NASDAQ:PETX)?
    Simply Wall St.4 months ago

    When Can We Expect A Profit From Aratana Therapeutics Inc (NASDAQ:PETX)?

    Aratana Therapeutics Inc’s (NASDAQ:PETX): Aratana Therapeutics, Inc., a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium.Read More...